SB-648868 is a potent, selective, and orally active antagonist of the orexin-1 (OX1) receptor. It is a synthetic small molecule with a complex structure featuring a benzofuran-4-carboxamide core linked to a piperidine ring bearing a 5-(4-fluorophenyl)-2-methylthiazole-4-carbonyl group, with a stereogenic center conferring the (S)-configuration. This compound was developed as a research tool and potential therapeutic agent for investigating the role of the orexin system in various central nervous system disorders. Its primary application is in preclinical research for conditions such as anxiety, stress, addiction, and compulsive behaviors, where OX1 receptor signaling is implicated. By selectively blocking the OX1 receptor, SB-648868 helps elucidate the specific contributions of this receptor subtype, distinct from the OX2 receptor, to physiological and pathological processes. As a well-characterized pharmacological probe, SB-648868 has been used extensively in academic and industrial research to validate the OX1 receptor as a drug target. Its status as a defined chemical entity with a specific biological target also qualifies it as a specialized building block or intermediate in the context of neuroscience drug discovery programs.